A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

LESSONS LEARNED. The combination of axitinib and crizotinib has a manageable safety and tolerability profile, consistent with the profiles of the individual agents when administered as monotherapy. The antitumor activity reported here for the combination axitinib/crizotinib does not support further...

Descripción completa

Detalles Bibliográficos
Autores principales: Michaelson, M. Dror, Gupta, Shilpa, Agarwal, Neeraj, Szmulewitz, Russell, Powles, Thomas, Pili, Roberto, Bruce, Justine Yang, Vaishampayan, Ulka, Larkin, James, Rosbrook, Brad, Wang, Erjian, Murphy, Danielle, Wang, Panpan, Lechuga, Maria Josè, Valota, Olga, Shepard, Dale R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738313/
https://www.ncbi.nlm.nih.gov/pubmed/31171735
http://dx.doi.org/10.1634/theoncologist.2018-0749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738313/
https://www.ncbi.nlm.nih.gov/pubmed/31171735
http://dx.doi.org/10.1634/theoncologist.2018-0749

Ejemplares similares